Deciding on Success Criteria for Predictability of Pharmacokinetic Parameters from In Vitro Studies: An Analysis Based on In Vivo Observations

被引:120
作者
Abduljalil, Khaled [1 ]
Cain, Theresa [1 ]
Humphries, Helen [1 ]
Rostami-Hodjegan, Amin [1 ,2 ]
机构
[1] Simcyp Ltd, Sheffield S2 4SU, S Yorkshire, England
[2] Univ Manchester, Manchester Pharm Sch, Manchester, Lancs, England
关键词
INTERINDIVIDUAL VARIABILITY; DRUG CLEARANCE; PREDICTION; METABOLISM; WARFARIN; CYP2C19; MODELS; PHASE; IVIVE;
D O I
10.1124/dmd.114.058099
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Prediction accuracy of pharmacokinetic parameters is often assessed using prediction fold error, i.e., being within 2-, 3-, or n-fold of observed values. However, published studies disagree on which fold error represents an accurate prediction. In addition, "observed data" from only one clinical study are often used as the gold standard for in vitro to in vivo extrapolation (IVIVE) studies, despite data being subject to significant interstudy variability and subjective selection from various available reports. The current study involved analysis of published systemic clearance (CL) and volume of distribution at steady state (V-ss) values taken from over 200 clinical studies. These parameters were obtained for 17 different drugs after intravenous administration. Data were analyzed with emphasis on the appropriateness to use a parameter value from one particular clinical study to judge the performance of IVIVE and the ability of CL and Vss values obtained from one clinical study to "predict" the same values obtained in a different clinical study using the n-fold criteria for prediction accuracy. The twofold criteria method was of interest because it is widely used in IVIVE predictions. The analysis shows that in some cases the twofold criteria method is an unreasonable expectation when the observed data are obtained from studies with small sample size. A more reasonable approach would allow prediction criteria to include clinical study information such as sample size and the variance of the parameter of interest. A method is proposed that allows the "success" criteria to be linked to the measure of variation in the observed value.
引用
收藏
页码:1478 / 1484
页数:7
相关论文
共 19 条
  • [1] Assessment of Activity Levels for CYP2D6*1, CYP2D6*2, and CYP2D6*41 Genes by Population Pharmacokinetics of Dextromethorphan
    Abduljalil, K.
    Frank, D.
    Gaedigk, A.
    Klaassen, T.
    Tomalik-Scharte, D.
    Jetter, A.
    Jaehde, U.
    Kirchheiner, J.
    Fuhr, U.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2010, 88 (05) : 643 - 651
  • [2] Allelic variants in the CYP2C9 and VKORC1 loci and interindividual variability in the anticoagulant dose effect of warfarin in Italians
    Borgiani, Paold
    Ciccacci, Cinzia
    Forte, Vittorio
    Romano, Silvia
    Federici, Giorgio
    Novelli, Giuseppe
    [J]. PHARMACOGENOMICS, 2007, 8 (11) : 1545 - 1550
  • [3] EFFECT OF AGING ON THE HEPATIC CLEARANCE OF PROPRANOLOL
    CASTLEDEN, CM
    GEORGE, CF
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1979, 7 (01) : 49 - 54
  • [4] Application of IVIVE and PBPK modeling in prospective prediction of clinical pharmacokinetics: strategy and approach during the drug discovery phase with four case studies
    Chen, Yuan
    Jin, Jin Y.
    Mukadam, Sophie
    Malhi, Vikram
    Kenny, Jane R.
    [J]. BIOPHARMACEUTICS & DRUG DISPOSITION, 2012, 33 (02) : 85 - 98
  • [5] Pharmacokinetics of beta-adrenoceptor blockers in obese and normal volunteers
    Cheymol, G
    Poirier, JM
    Carrupt, PA
    Testa, B
    Weissenburger, J
    Levron, JC
    Snoeck, E
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1997, 43 (06) : 563 - 570
  • [6] Methadone enantiomer plasma levels, CYP2B6, CYP2C19, and CYP2C9 genotypes, and response to treatment
    Crettol, S
    Déglon, JJ
    Besson, J
    Croquette-Krokkar, M
    Gothuey, I
    Hämmig, R
    Monnat, M
    Hüttemann, H
    Baumann, P
    Eap, CB
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2005, 78 (06) : 593 - 604
  • [7] Sources of interindividual variability in IVIVE of clearance: an investigation into the prediction of benzodiazepine clearance using a mechanistic population-based pharmacokinetic model
    Cubitt, Helen E.
    Yeo, Karen R.
    Howgate, Eleanor M.
    Rostami-Hodjegan, Amin
    Barter, Zoe E.
    [J]. XENOBIOTICA, 2011, 41 (08) : 623 - 638
  • [8] Polymorphic CYP2C19 and N-acetylation:: human variability in kinetics and pathway-related uncertainty factors
    Dorne, JLCM
    Walton, K
    Renwick, AG
    [J]. FOOD AND CHEMICAL TOXICOLOGY, 2003, 41 (02) : 225 - 245
  • [9] Human variability in polymorphic CYP2D6 metabolism: is the kinetic default uncertainty factor adequate?
    Dorne, JLCM
    Walton, K
    Slob, W
    Renwick, AG
    [J]. FOOD AND CHEMICAL TOXICOLOGY, 2002, 40 (11) : 1633 - 1656
  • [10] Prediction of Phase I single-dose pharmacokinetics using recombinant cytochromes P450 and physiologically based modelling
    Gibson, C. R.
    Bergman, A.
    Lu, P.
    Kesisoglou, F.
    Denney, W. S.
    Mulrooney, E.
    [J]. XENOBIOTICA, 2009, 39 (09) : 637 - 648